Waves

Wave Life Sciences is a clinical-stage genetic medicines company developing RNA-targeted therapies for both rare and common diseases. Its core capabilities span RNA editing, splicing, RNA interference, and allele-selective antisense silencing, enabled by its PRISM platform for designing stereopure oligonucleotides. The company’s lead clinical programs include WVE-006 for alpha-1 antitrypsin deficiency, WVE-N531 for Duchenne muscular dystrophy, WVE-003 for Huntington's disease, and WVE-007 for obesity. Wave is publicly traded on Nasdaq and is focused on building differentiated, potentially disease-modifying medicines across liver, muscle, and central nervous system disorders.